Integrated biotechnology drug major Biocon Limited, which stormed into Pakistan seven years ago with a range of active pharmaceutical ingredients (APIs), is now all set to market BIOMAb EGFR, its oncology drug for head and neck cancer, in the region. The company has managed to tap its contacts in the region by granting an exclusive license to Ferozsons Laboratories Ltd, the first local pharmaceutical company to be listed on the Pakistan stock exchange, for marketing BIOMAb EGFR in Pakistan early this year.
With cancer cases showing a high rate of incidence in Pakistan, Biocon has managed to be in touch with the oncologists to market BIOMAb through a strategic medical marketing route. Biocon has managed to tap 20 per cent of the key opinion leaders in oncology care.
Speaking to Chronicle Pharmabiz, Rakesh Bamzai, president, marketing, Biocon Limited, said, "The Pakistan market has a huge potential. So far we have received good response to our drugs and we have made our presence felt in the market."
The company is confident of grabbing about 30-40 per cent share of the head and neck cancer market in the region within the next two years, he said. Apart, clinical trials are on for other cancers with the same drug for which Biocon has entered into a partnership, he added.